ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and ...
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The ...
The firm’s 50 day moving average is $0.42 and its 200 day moving average is $0.57. Quoin Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $1.57. In other news, COO Denise P.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has reported significant progress in 2024, highlighting its advancements in the clinical development of QRX003, a treatment for Netherton Syndrome. CEO ...
ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare ...
Quoin Pharmaceuticals (QNRX) announced recent corporate accomplishments and provided an update on its fourth quarter and full-year 2024 progress. Quoin CEO Michael Myers said, “2024 was without ...
ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback